LataMed AI Corp. (OTC: LMED) today provided shareholders with an update on the implementation of its previously announced 5-for-1 forward stock split and the related mandatory share exchange process. As of July 7, 2026, the Company has provided FINRA with all requested information and documentation. Management presently anticipates that the corporate action may become effective within approximately the next week, subject to FINRA's review and final processing. The Company will provide a further update as soon as FINRA establishes the official effective date.
The forward stock split will be implemented in conjunction with the assignment of a new CUSIP number, 21116R404, replacing the current CUSIP upon effectiveness. The Company wishes to provide additional information to assist shareholders in understanding how the mandatory exchange process is expected to be administered. Shareholders holding shares through a brokerage account generally are not required to take any action, as brokerage firms are expected to process the mandatory exchange automatically. Registered book-entry shareholders also are not required to submit any documentation, as the transfer agent is expected to update accounts to reflect the post-split share balance and new CUSIP. Physical stock certificate holders are not required to immediately surrender their certificates, but existing certificates will represent the pre-exchange security. When a shareholder elects to submit a physical certificate for transfer, sale, or exchange, the certificate will be processed in accordance with the mandatory exchange procedures, and the transfer agent will issue the appropriate number of post-split shares under the new CUSIP.
Dr. Kevin Rodan Levy, Chief Executive Officer, stated: “We want to ensure that our shareholders clearly understand how the forward stock split and mandatory exchange process will be implemented. As we move beyond the implementation, management intends to focus on advancing the Company's telemedicine platform while continuing to pursue licensing and commercialization opportunities for our CardioAI, PulmoAI, and NeuroAI artificial intelligence platforms. We believe these initiatives represent important components of our long-term strategy to build an integrated digital healthcare ecosystem throughout Latin America.”
Management believes the forward stock split supports the Company's continued corporate development and broader strategic initiatives while facilitating implementation of the new CUSIP and updated capital structure. The Company encourages shareholders with questions to contact their brokerage firm or the Company's transfer agent once detailed exchange instructions become available. For additional information, please visit https://latamed.ai or review the Company's filings with the U.S. Securities and Exchange Commission at www.sec.gov.
